Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

ge for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    BioMS Medical Corp.
    (A Development Stage Corporation)
    Consolidated Balance Sheet
    December 31, 2008 and 2007
    -------------------------------------------------------------------------

    (expressed in thousands of Canadian dollars)

                                                             2008       2007
                                                                $          $

'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... and HEIDELBERG , Germany ... Addresses unmet need in treatment of millions of ... has been granted a patent in Europe ... patent supports Molecular Health,s discovery that EPHB4 is a novel ... promotes tumor growth. EPO stimulates the production of red blood ...
(Date:4/27/2015)... 2015 Diasome Pharmaceuticals, Inc. (“Diasome”) ... Joslin Diabetes Center (“Joslin”) to collaborate on the ... novel Hepatocyte Directed Vesicle (“HDV”) targeting system for ... , Located in Boston, Massachusetts, Joslin is the ... organization dedicated to the prevention, treatment and cure ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... Cylene Pharmaceuticals today announced,the initiation of a Phase ... carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers arising from ... "Quarfloxin (CX-3543) is a small molecule ... abnormal nucleoli of cancer cells, thereby,selectively inducing apoptotic ...
... PAREXEL International,Corporation (Nasdaq: PRXL ), ... the Company has been named the "Best Contract,Research ... award was,presented to PAREXEL at the fourth annual ... London, England. The Scrip Awards are designed to,celebrate ...
... Precision(R), Inc. a,leading provider of imaging, measurement, and ... that it will introduce a new imaging,system at ... conference with,twice the resolution of traditional microscopes. ... system developed by scientists at the, University of ...
Cached Biology Technology:Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Research Institute (NHGRI), one of the National Institutes ... Sequencing Research Network will begin sequencing 12 more ... and several important insects, as part of its ... genome. , The National Advisory Council for Human ...
... a marvel of versatility, creating a variety of cells that ... out these tasks, immune cells follow a career path that ... in the May 2005 issue of Immunity, Fox Chase Cancer ... Dietmar J. Kappes, Ph.D., show that cell-receptor signaling strength influences ...
... the biological literature resides in full text articles, instead ... publicly available literature data mining tools. Most literature mining ... extracted from curated gene or protein databases. This is ... the many name variants which are used to refer ...
Cached Biology News:NHGRI targets 12 more organisms for genome sequencing 2NHGRI targets 12 more organisms for genome sequencing 3NHGRI targets 12 more organisms for genome sequencing 4NHGRI targets 12 more organisms for genome sequencing 5Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3